Introduction
Since the beginning of anti-covid-19 vaccination campaigns in different countries, more frequent and stronger adverse effects of mRNA vaccines were reported in subjects having been already infected with SARS-Cov-2, than in naïve individuals (1-3). Generally, such patients experienced amplified systemic adverse effects, such as fatigue, headache, chills, fever, and muscle or joint pains. However, information is lacking in patients having suffered and recovered from more or less severe forms of covid-19. The present clinical history highlights an unusual strong reactivation of a pulmonary pathology beginning some hours after the administration of a first dose of the BNT162b2 mRNA vaccine in a patient having presented a symptomatic pulmonary form of covid-19 one month before. The lessons of this clinical history in terms of consequences for the continuation of vaccination campaigns in previously infected patients, as well as the possible mechanisms involved are discussed.